Approximately 15 to 30 % of relapsing GCB- and ABC-DLBCL patients have c-MYC/BCL2 or c-MYC/BCL6 double-hit DLBCLs with high co-expression of c-MYC and BCL2 or BCL6 proteins [85, 174]. Here, BCL6 is linked to diffuse large B-cell lymphoma.